Drugs / NIP292
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04720443 | Nov 2019 → Jul 2022 | idiopathic pulmonary fibrosis | The National Institutes of Pharmaceutical R&D Co. Ltd, China | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIP292 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04720443 ↗ |
| Route | Oral | “NIP292 (oral tablet at 10 mg) or placebo” NCT04720443 ↗ |